Skip to main content
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Home
Table of Contents
Test, Evaluate, Monitor
Treatment-Naive Patients
Treatment-Experienced Patients
Unique & Key Populations
About the Guidance
Home
Table of Contents
Introduction
Methods
Methods Table 1
Methods Table 2
Methods Table 3 Abbreviations
References
Test, Evaluate, Monitor
Testing and Linkage to Care
When and in Whom
Cost, Reimbursement, and Cost-Effectiveness
Monitoring
Incomplete Adherence
HCV Resistance
Treatment-Naive
Simplified: No Cirrhosis
Simplified: Comp. Cirrhosis
Decompensated Cirrhosis
Genotype 1
GT1a: No Cirrhosis
GT1a: Compensated
GT1b: No Cirrhosis
GT1b: Compensated
Genotype 2
GT2 : No Cirrhosis
GT2 : Compensated
Genotype 3
GT3 : No Cirrhosis
GT3 : Compensated
Genotype 4
GT4 : No Cirrhosis
GT4 : Compensated
Genotype 5 or 6
Treatment-Experienced
SOF-Based and ELB/GRZ Treatment Failures
G/P Treatment Failures
Multiple DAA Treatment Failures
Decompensated Cirrhosis
Unique & Key Populations
HIV/HCV Coinfection
Decompensated Cirrhosis
Post Liver Transplant
Organs from HCV-Viremic Donors
Renal Impairment
Kidney Transplant
Acute Infection
HCV in Pregnancy
HCV in Children
PWID, MSM & Corrections
People Who Inject Drugs
Men Who Have Sex With Men
Correctional Settings
About
Announcements
Organizations
Panel
Disclosures
Process
Citing and Permissions
Survey
Website Policies
Contact
You are here
Home
›
References
References
Filters:
Author
is
U.S. Congressional Budget Office
[Clear All Filters]
U
Prescription drug pricing in the private sector
. 2015;2015(2015, July 29).
Top
